| Name | Title | Contact Details |
|---|
Medical Information Technology, Inc. (MEDITECH) is engaged in developing, manufacturing and marketing of computer software products for the hospital industry. The wholly owned subsidiary of the Company is Patient Care Technologies, Inc. (PtCT).
Integris Southwest Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Integris Southwest Medical Center is based in Oklahoma City, OK. You can find more information on Integris Southwest Medical Center at www.integrishealth.com
Blue Cross and Blue Shield of Minnesota is a taxable, nonprofit organization with a mission to make a healthy difference in people’s lives. Chartered in 1933 as Minnesota’s first health plan, we’ve promoted wider, more economical and timely availability of health services for the people of Minnesota for more than 75 years. A GOLD STANDARD HEALTH EMPLOYER Blue Cross was recently named a Gold Standard employer from the CEO Roundtable on Cancer from the American Cancer Society. We earned this award because we`re achieving the highest criteria for workplace programs that discourage tobacco use, encourage physical activity, promote healthy nutrition, support prevention and access to quality treatment
Joimax USA is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.